Welcome!

News Feed Item

Meditope Biosciences Appoints Prominent Scientific Advisory Board

PASADENA, Calif., Jan. 14, 2014 /PRNewswire/ -- Meditope Biosciences, Inc., a biotechnology company developing antibody-based products, today announced the appointment of inaugural members of its newly-formed scientific advisory board.  The board will leverage its extensive experience in protein engineering to advise the company to help advance its proprietary monoclonal antibody (mAb) technology platform for the development of novel antibody-drug conjugates.

"We are very proud to appoint these prominent members of science and industry, as we work to quickly and efficiently apply our exciting new technology to a spectrum of drug development programs," said Stephanie Hsieh, Meditope's president and chief executive officer.  "Recently, we have made significant progress to establish our technology platform and initiate key studies that will inform our cancer drug development programs.  The strategic input from these experienced advisors will be key as we seek out meaningful development partnerships and maximize opportunities to deploy our best in class antibody-drug conjugate technology."

Members of the scientific advisory board include:

  • Peter B. Dervan, PhD, Bren Professor of Chemistry at the California Institute of Technology.  He is also a member of the National Academy of Sciences, the Institute of Medicine, the American Academy of Arts & Sciences, the American Philosophical Society, and a Foreign Member of both the French and German Academies of Science.  Dr. Dervan was awarded the National Medal of Science in 2006.  He has served on numerous Scientific Advisory Boards, including that of Gilead Sciences, Inc.  Dr. Dervan is recognized for creating a new field of bioorganic chemistry directed towards understanding the chemical principles for the sequence specific recognition of DNA.
  • Iqbal S. Grewal, PhD, DSc, FRCPath, Chief Scientific Officer and a director of ImmunGene, Inc.  Prior to joining ImmunGene, Dr. Grewal served as Vice President of Preclinical Therapeutics at Seattle Genetics, where he managed preclinical translational research functions for development of monoclonal antibodies and antibody-drug conjugates as therapeutics in the areas of oncology and autoimmunity.  His career also includes discovery research and preclinical development of biologics at Genentech, as well as various research positions at Yale University School of Medicine and the University of California, Los Angeles.  He is a fellow of the Royal College of Pathologists, London and member of several distinguished societies. He has extensive experience in the discovery and development of innovative protein-based biotherapeutics in many disease areas.
  • Arthur D. Riggs, PhD, Director Emeritus and current Chair of the Diabetes Research Department of the Beckman Research Institute at City of Hope. Dr. Riggs was the founding dean of the City of Hope's graduate school.  He is also a Member of the National Academy of Sciences. Previously, Dr. Riggs worked with Genentech to express the first artificial genes, for somatostatin and insulin, in bacteria.  His work helped form the bedrock of the modern biotechnology industry, enabling the large-scale manufacture of protein drugs, like synthetic human insulin, and developing recombinant DNA techniques that are the basis for creating therapeutic monoclonal antibodies.
  • John C. Williams, PhD, Co-founder of Meditope Biosciences and Associate Professor of Molecular Medicine at the Beckman Research Institute of the City of Hope, where he also serves as a member of the Developmental Cancer Therapeutics Program as well as Co-Director of the Drug Discovery and Structural Biology Core.  Dr. Williams' research centers on the application of structural and biophysical methods to understand the biological role of multivalency and energy additivity on multicomponent, macromolecular complexes and how to manipulate these properties to develop novel, highly specific antagonists.   Recently, his lab discovered the meditope binding site while investigating alternative masking agents for cetuximab. This discovery led to the founding of Meditope Biosciences.

About Meditope Biosciences, Inc. 
Meditope Biosciences is a biotechnology company developing best-in-class antibody-based cancer products.  Discovered at City of Hope, a National Cancer Institute designated Comprehensive Cancer Center, Meditope's technology is capable of turning any mAb into a proprietary, site-specific "Lego-like" system that is able to attach and detach drugs to antibodies without the need for chemical conjugation.  The result is a memAb (meditope-enabled mAb) product, which is anticipated to be significantly more effective and offer multiple manufacturing advantages compared to existing antibody-drug conjugate technologies.  The technology has the potential to advance the antibody market by producing an array of new therapeutic and diagnostic products.  More information regarding the company can be found by visiting www.meditope.com.

SOURCE Meditope Biosciences, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settl...
No hype cycles or predictions of zillions of things here. IoT is big. You get it. You know your business and have great ideas for a business transformation strategy. What comes next? Time to make it happen. In his session at @ThingsExpo, Jay Mason, Associate Partner at M&S Consulting, presented a step-by-step plan to develop your technology implementation strategy. He discussed the evaluation of communication standards and IoT messaging protocols, data analytics considerations, edge-to-cloud tec...
In his session at @ThingsExpo, Dr. Robert Cohen, an economist and senior fellow at the Economic Strategy Institute, presented the findings of a series of six detailed case studies of how large corporations are implementing IoT. The session explored how IoT has improved their economic performance, had major impacts on business models and resulted in impressive ROIs. The companies covered span manufacturing and services firms. He also explored servicification, how manufacturing firms shift from se...
IoT is at the core or many Digital Transformation initiatives with the goal of re-inventing a company's business model. We all agree that collecting relevant IoT data will result in massive amounts of data needing to be stored. However, with the rapid development of IoT devices and ongoing business model transformation, we are not able to predict the volume and growth of IoT data. And with the lack of IoT history, traditional methods of IT and infrastructure planning based on the past do not app...
For far too long technology teams have lived in siloes. Not only physical siloes, but cultural siloes pushed by competing objectives. This includes informational siloes where business users require one set of data and tech teams require different data. DevOps intends to bridge these gaps to make tech driven operations more aligned and efficient.
For organizations that have amassed large sums of software complexity, taking a microservices approach is the first step toward DevOps and continuous improvement / development. Integrating system-level analysis with microservices makes it easier to change and add functionality to applications at any time without the increase of risk. Before you start big transformation projects or a cloud migration, make sure these changes won’t take down your entire organization.
It is ironic, but perhaps not unexpected, that many organizations who want the benefits of using an Agile approach to deliver software use a waterfall approach to adopting Agile practices: they form plans, they set milestones, and they measure progress by how many teams they have engaged. Old habits die hard, but like most waterfall software projects, most waterfall-style Agile adoption efforts fail to produce the results desired. The problem is that to get the results they want, they have to ch...
Organizations planning enterprise data center consolidation and modernization projects are faced with a challenging, costly reality. Requirements to deploy modern, cloud-native applications simultaneously with traditional client/server applications are almost impossible to achieve with hardware-centric enterprise infrastructure. Compute and network infrastructure are fast moving down a software-defined path, but storage has been a laggard. Until now.
Without a clear strategy for cost control and an architecture designed with cloud services in mind, costs and operational performance can quickly get out of control. To avoid multiple architectural redesigns requires extensive thought and planning. Boundary (now part of BMC) launched a new public-facing multi-tenant high resolution monitoring service on Amazon AWS two years ago, facing challenges and learning best practices in the early days of the new service.
Digital Transformation is much more than a buzzword. The radical shift to digital mechanisms for almost every process is evident across all industries and verticals. This is often especially true in financial services, where the legacy environment is many times unable to keep up with the rapidly shifting demands of the consumer. The constant pressure to provide complete, omnichannel delivery of customer-facing solutions to meet both regulatory and customer demands is putting enormous pressure on...
The best way to leverage your CloudEXPO | DXWorldEXPO presence as a sponsor and exhibitor is to plan your news announcements around our events. The press covering CloudEXPO | DXWorldEXPO will have access to these releases and will amplify your news announcements. More than two dozen Cloud companies either set deals at our shows or have announced their mergers and acquisitions at CloudEXPO. Product announcements during our show provide your company with the most reach through our targeted audienc...
With 10 simultaneous tracks, keynotes, general sessions and targeted breakout classes, @CloudEXPO and DXWorldEXPO are two of the most important technology events of the year. Since its launch over eight years ago, @CloudEXPO and DXWorldEXPO have presented a rock star faculty as well as showcased hundreds of sponsors and exhibitors!
DXWorldEXPO LLC announced today that All in Mobile, a mobile app development company from Poland, will exhibit at the 22nd International CloudEXPO | DXWorldEXPO. All In Mobile is a mobile app development company from Poland. Since 2014, they maintain passion for developing mobile applications for enterprises and startups worldwide.
JETRO showcased Japan Digital Transformation Pavilion at SYS-CON's 21st International Cloud Expo® at the Santa Clara Convention Center in Santa Clara, CA. The Japan External Trade Organization (JETRO) is a non-profit organization that provides business support services to companies expanding to Japan. With the support of JETRO's dedicated staff, clients can incorporate their business; receive visa, immigration, and HR support; find dedicated office space; identify local government subsidies; get...
"Akvelon is a software development company and we also provide consultancy services to folks who are looking to scale or accelerate their engineering roadmaps," explained Jeremiah Mothersell, Marketing Manager at Akvelon, in this SYS-CON.tv interview at 21st Cloud Expo, held Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.